February 17, 2017 7:44am

 

Investors will need a drink to stay to maintain a high and handle the lows

 

As the fourth-quarter financial results continue, spending and cash positions are further revealed

 

Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector

 

Today’s headlights:  two (2) equities

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

 

Expectation will be the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions through this year 2017.

 

 

BUY: BLUE

SELL: CAPR

 

Indexes and ETFs: The IWM (-0.61%), IBB (-0.35%) and the XBI (-0.71%) are DOWN and XLV is NOT indicating

Dow futures are DOWN -0.21% and NASDAQ futures are DOWN -0.21%

 

U.S. stock index futures pointed to a lower open on Friday ahead of the Presidents' Day holiday weekend.

European markets moved lower, pausing for breath after a strong rally at the start of the week, as investors digested economic data and more earnings reports.

Asia markets finished mostly lower, as Samsung Group shares were in focus following the arrest of its chief.

Data docket: None

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) closed NEGATIVE on Thursday, POSITIVE on Wednesday, Tuesday, Monday and last Friday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

·         Thursday closed NEGATIVE with 26 decliners, 16 advancers and 1 flat;

·         Wednesday closed POSITIVE with 15 decliners, 25 advancers and 3 flats;

·         Tuesday closed POSITIVE with  20 decliners, 21 advancers and 2 flats;

·         Monday closed POSITIVE with 15 decliners, 24 advancers and 4 flats;

·         Friday closed POSITIVE with 15 decliners, 24 advancers and 4 flats;

 

 

Remembering Thursday’s closing bell newsletter, “Shares shrink as share pricing uncertainty increases. Without speculation, the sector is out of upside

  • Reiterating, “From my point of view, the sentiment that exists today borders on hunger for something to happen and then be stuck with overconfidence.  Of course, even with unique variables showing us that risk perceptions have absolutely increased, no one knows for sure what is going to happen.” 

As further Q4/16 financial results are released, we will see the fragility of the sector.

  • That fragility is further enhanced by those who will attempt to force their way through the capital market open window for financing.

The problem is the capital access is getting lower every session.

 

One “named” failure will set the tone for other companies to right-side their focus to investors; we at the moment are too dependent on bottom-feeding warrant clippers for investment.

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

·         The iShares Nasdaq Biotechnology (IBB) closed  Thursday down -0.67% and is DOWN -0.35% in Friday’s pre-market;

·         The SPDR S&P Biotech ETF (XBI) closed Thursday down -0.61% and is DOWN -0.71% in Friday’s after-market;

·         The Health Care Select Sector SPDR ETF (XLV) closed down -0.14% Thursday and NOT indicating in Friday’s pre-market;

·         The iShares Russell 2000 (IWM) closed down -0.39% on Thursday and is DOWN -0.61% in Friday’s pre-market

                                                                                   

 

Companies in my headlights:

bluebird bio (BLUE) closed DOWN -$2.70 to $76.55. Up, down, round and down again - the wishy-washy movent of the shares yet, momentum sets the score these days. The aftermarket indication is positive +$0.14 – BUY;

Capricor (CAPR) closed UP +$0.01 to $3.16 following Wednesday’s $3.15 (+$0.16), Tuesday’s $2.98 (+$0.16). Is the stock getting ahead of itself? February 6, the stock traded at $2.40, January 30/16 the stock traded at $2.18 as the year (January/3/17) started at $2.55. CAPR has elected to terminate its license agreement with the Mayo Clinic relating to natriuretic peptide receptor agonists, including Cenderitide – all those dollars wasted – Maintaining SELL;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.